Objective:It aims to build a scientific and reasonable occupational safety and health risk assessment index system for chemical enterprises, and provide theoretical guidance and scientific basis for the systematic identification, quantification and prevention and control of occupational safety and healthrisk in chemical enterprises.Methods:February 2024, based on relevant literature, national and industry standards as the theoretical foundation, Broussonetia papyrifera established an occupational safety and health risk assessment indicator system for chemical enterprises. Twenty-three experts in occupational health and related fields were invited to score the importance of the indicators; Broussonetia papyrifera constructed an AHP model to calculate the individual expert indicator weights and test matrix consistency, applied the systematic clustering method to allocate expert weights, and employed the weighted average method of weight vectors to calculate the expert group indicator weights.Results:The index system includes 5 first-level indicators, 15 second-level indicators and 42 third-level indicators.A total of 22 experts participated in the questionnaire survey, and the degree of expert activity was 96.5% (22/23), and the mean authority coefficient was 0.88, the questionnaire Cronbach's α coefficient was 0.954. The top three are production facilities, equipment and process technology (0.3694), occupational harmful factors (0.2381) and occupational health management (0.1486). Its subordinate secondary index production technology, production facilities and equipment, chemical harmful factors and tertiary indicators of raw materials selection, process technology, equipment quality and safety weight is also higher than other indicators of the same level.Conclusion:Based on the AHP model and systematic cluster analysis, the occupational safety and health risk assessment index system established for Broussonetia papyrifera chemical enterprises is scientifically reasonable and can provide reference for corporate risk assessment.

Hepatocellular carcinoma(HCC)is the fourth leading cause of cancer death in the world,and its prognosis is poor.Most HCC patients are diagnosed at an advance stage and are not candidates for surgery.Even if the early-stage tumor is resected,HCC patients tend to relapse within 5 years.In the era of targeted therapy and immunotherapy,neoadjuvant therapy has gained increasing attention and recommendation.For HCC patients with high recurrence risk,neoadjuvant therapy refers to preoperative local or systemic therapy,which can reduce tumor burden,remove tiny lesions,widen surgical margin,and reduce the recurrence risk.However,if the neoadjuvant therapy is not optimal,the timing of surgery will be delayed,resulting in disease progression or even loss of the chance for surgery.This article reviews the research progress of neoadjuvant therapy for HCC.

Background and aims:Advanced hepatocellular carcinoma(HCC)with pulmonary metastasis(PM)has a poor prognosis,and optimal treatment strategies remain controversial.This study aimed to compare the long-term outcomes of patients with advanced HCC with PM who were treated with resection of pul-monary metastases versus those treated with targeted therapies combined with immunotherapy.Methods:A retrospective analysis was conducted on the medical records of HCC patients with PM who underwent either pulmonary metastasectomy or immunotherapy combined with targeted therapies at the Eastern Hepatobiliary Surgery Hospital,Changhai Hospital of Shanghai,Fujian Provincial Hospital,and West China Hospital of Sichuan University from September 2013 to October 2022.One-to-one propensity score matching(PSM)was employed to control the influence of potential confounders,and the survival outcomes were compared.Results:A total of 119 HCC patients with PM were included in this study.The overall survival(OS)of patients who underwent pulmonary metastasectomy was significantly longer than that of patients who received immunotherapy targeted combinations(OS:1-year,80.0％vs.59.3％;2-year,31.7％vs.20.3％;3-year,20.0％vs.0;P＜0.001).After PSM,the long-term prognosis of the pulmonary metastasectomy group remained significantly better than that of the immunotherapy combination group(OS:1-year,87.0％vs.69.6％;2-year,34.8％vs.30.4％;3-year,21.7％vs.0;P=0.005).Multivariate analysis revealed that treat-ment allocation(hazard ratio(HR)=2.177,95％confidence interval(CI)=1.068-4.439)and hepatic tumor T stage(HR=2.342,95％CI=1.209-4.538)were independent risk factors for OS.Conclusions:Pulmonary metastasectomy was associated with improved survival compared to immu-notherapy combined with targeted therapies and may represent an optimal treatment option for highly selected HCC patients with resectable PM.

Hepatocellular carcinoma(HCC)is characterized by a high propensity for vascular invasion,frequently leading to the formation of tumor thrombi,which significantly affect prognosis and therapeutic decision-making.Microvascular invasion(MVI)is a key predictor of postoperative recurrence,whereas the presence of macrovascular tumor thrombus indicates advanced disease.In recent years,notable progress has been made in the standardized diagnosis,preoperative prediction,and individualized treatment strategies for vascular tumor thrombi.The integration of radiomics and biomarkers has markedly improved the accuracy of preoperative MVI prediction,while various neoadjuvant and adjuvant treatment approaches have shown potential in controlling postoperative recurrence.Despite continuous optimization of diagnostic and therapeutic systems,challenges remain,including tumor heterogeneity,the lack of dynamic monitoring tools,and the difficulty in improving survival rates in high-risk patients.This review summarizes recent advances in the field of vascular tumor thrombi in HCC,aiming to provide theoretical support for clinical practice and to promote the development of individualized precision therapy.

Objective:It aims to build a scientific and reasonable occupational safety and health risk assessment index system for chemical enterprises, and provide theoretical guidance and scientific basis for the systematic identification, quantification and prevention and control of occupational safety and healthrisk in chemical enterprises.Methods:February 2024, based on relevant literature, national and industry standards as the theoretical foundation, Broussonetia papyrifera established an occupational safety and health risk assessment indicator system for chemical enterprises. Twenty-three experts in occupational health and related fields were invited to score the importance of the indicators; Broussonetia papyrifera constructed an AHP model to calculate the individual expert indicator weights and test matrix consistency, applied the systematic clustering method to allocate expert weights, and employed the weighted average method of weight vectors to calculate the expert group indicator weights.Results:The index system includes 5 first-level indicators, 15 second-level indicators and 42 third-level indicators.A total of 22 experts participated in the questionnaire survey, and the degree of expert activity was 96.5% (22/23), and the mean authority coefficient was 0.88, the questionnaire Cronbach's α coefficient was 0.954. The top three are production facilities, equipment and process technology (0.3694), occupational harmful factors (0.2381) and occupational health management (0.1486). Its subordinate secondary index production technology, production facilities and equipment, chemical harmful factors and tertiary indicators of raw materials selection, process technology, equipment quality and safety weight is also higher than other indicators of the same level.Conclusion:Based on the AHP model and systematic cluster analysis, the occupational safety and health risk assessment index system established for Broussonetia papyrifera chemical enterprises is scientifically reasonable and can provide reference for corporate risk assessment.

Hepatocellular carcinoma(HCC)is characterized by a high propensity for vascular invasion,frequently leading to the formation of tumor thrombi,which significantly affect prognosis and therapeutic decision-making.Microvascular invasion(MVI)is a key predictor of postoperative recurrence,whereas the presence of macrovascular tumor thrombus indicates advanced disease.In recent years,notable progress has been made in the standardized diagnosis,preoperative prediction,and individualized treatment strategies for vascular tumor thrombi.The integration of radiomics and biomarkers has markedly improved the accuracy of preoperative MVI prediction,while various neoadjuvant and adjuvant treatment approaches have shown potential in controlling postoperative recurrence.Despite continuous optimization of diagnostic and therapeutic systems,challenges remain,including tumor heterogeneity,the lack of dynamic monitoring tools,and the difficulty in improving survival rates in high-risk patients.This review summarizes recent advances in the field of vascular tumor thrombi in HCC,aiming to provide theoretical support for clinical practice and to promote the development of individualized precision therapy.

Objective:To understand the utilization and characteristics of outpatient services for pneumoconiosis patients within two weeks in Chongqing, and analyze the influencing factors, so as to provide reference for relevant policy making.Methods:From October 2020 to October 2022, 1771 pneumoconiosis patients who met the inclusion criteria were selected by multi-stage stratified random cluster sampling. A questionnaire survey was conducted on their basic situation, utilization of outpatient services within two weeks, treatment for pneumoconiosis-related symptoms, and selection of medical service institutions using χ 2-test and logistic regression analysis. Results:All the 1771 pneumoconiosis patients were male, with the average age of (56.1±10.19) years old. In the pneumoconiosis patients were treated in outpatient department within 2 weeks.40.0% (204/510) of aged 41~50 years Rural patients accounted for 87.8% (448/510) ; 65.1% (332/510) of silicosis patients, 37.5% (191/510) of stage II patients, 75.1% (383/510) of patients did not continue to engage in dust work after diagnosis of pneumoconiosis, and 57.1% (291/510) of patients never had work-related injury insurance at work. The outpatient rate within two weeks of pneumoconiosis related assistance and subsistence allowance was 17.6% (90/510) and 12.5% (64/510), respectively. The average self-health score of the patients was (52.9±16.2). 28.2% of the patients had purchased work-related injury insurance; Among the 1204 patients who received the treatment within two weeks, 42.2% were in the outpatient department, 20.7% were in the inpatient department, and 36.9% were self-buyers. There was a significant difference between the different treatment methods of the patients (χ 2=27.53, P<0.05). There was a significant difference in patients from different residence choosing to visit different medical institutions (χ 2=13.97, P<0.05). The stage of pneumoconiosis, presence of complications, presence of work injury insurance, self-health score, and whether he/she has been hospitalized in the past year are the important factors affecting the outpatient treatment of pneumoconiosis patients. Conclusion:The utilization of outpatient service of pneumoconiosis patients is influenced by demographic sociology, social support and disease characteristics. The quality of occupational disease medical service in primary health institutions should be strengthened so that pneumoconiosis patients can get convenient and effective treatment. Establish a more perfect social security support system to reduce the disease burden of pneumoconiosis patients.

Objective:To understand the utilization and characteristics of outpatient services for pneumoconiosis patients within two weeks in Chongqing, and analyze the influencing factors, so as to provide reference for relevant policy making.Methods:From October 2020 to October 2022, 1771 pneumoconiosis patients who met the inclusion criteria were selected by multi-stage stratified random cluster sampling. A questionnaire survey was conducted on their basic situation, utilization of outpatient services within two weeks, treatment for pneumoconiosis-related symptoms, and selection of medical service institutions using χ 2-test and logistic regression analysis. Results:All the 1771 pneumoconiosis patients were male, with the average age of (56.1±10.19) years old. In the pneumoconiosis patients were treated in outpatient department within 2 weeks.40.0% (204/510) of aged 41~50 years Rural patients accounted for 87.8% (448/510) ; 65.1% (332/510) of silicosis patients, 37.5% (191/510) of stage II patients, 75.1% (383/510) of patients did not continue to engage in dust work after diagnosis of pneumoconiosis, and 57.1% (291/510) of patients never had work-related injury insurance at work. The outpatient rate within two weeks of pneumoconiosis related assistance and subsistence allowance was 17.6% (90/510) and 12.5% (64/510), respectively. The average self-health score of the patients was (52.9±16.2). 28.2% of the patients had purchased work-related injury insurance; Among the 1204 patients who received the treatment within two weeks, 42.2% were in the outpatient department, 20.7% were in the inpatient department, and 36.9% were self-buyers. There was a significant difference between the different treatment methods of the patients (χ 2=27.53, P<0.05). There was a significant difference in patients from different residence choosing to visit different medical institutions (χ 2=13.97, P<0.05). The stage of pneumoconiosis, presence of complications, presence of work injury insurance, self-health score, and whether he/she has been hospitalized in the past year are the important factors affecting the outpatient treatment of pneumoconiosis patients. Conclusion:The utilization of outpatient service of pneumoconiosis patients is influenced by demographic sociology, social support and disease characteristics. The quality of occupational disease medical service in primary health institutions should be strengthened so that pneumoconiosis patients can get convenient and effective treatment. Establish a more perfect social security support system to reduce the disease burden of pneumoconiosis patients.

Purpose: The prognosis of patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombus (PVTT) is extremely poor, and systemic therapy is currently the mainstream treatment. This study aimed to assess the efficacy and safety of lenvatinib combined with anti–programmed cell death-1 antibodies and transcatheter arterial chemoembolization (triple therapy) in patients with HCC and PVTT. Materials and Methods: This retrospective multicenter study included patients with HCC and PVTT who received triple therapy, were aged between 18 and 75 years, classified as Child-Pugh class A or B, and had at least one measurable lesion. The overall survival (OS), progression-free survival (PFS), objective response rates, and disease control rates were analyzed to assess efficacy. Treatment-related adverse events were analyzed to assess safety profiles. Results: During a median follow-up of 11.23 months (range, 3.07 to 34.37 months), the median OS was greater than 24 months, and median PFS was 12.53 months. The 2-year OS rate was 54.9%. The objective response rate and disease control rate were 69.8% (74/106) and 84.0% (89/106), respectively; 20.8% (22/106) of the patients experienced grade 3/4 treatment-related adverse events and no treatment-related deaths occurred. The conversion rate to liver resection was 31.1% (33/106), with manageable postoperative complications. The median OS was not reached in the surgery group, but was 19.08 months in the non-surgery group. The median PFS in the surgery and non-surgery groups were 20.50 and 9.00 months, respectively. Conclusion Triple therapy showed promising survival benefits and high response rates in patients with HCC and PVTT, with manageable adverse effects.